Summary & Overview
HCPCS C1818: Integrated Keratoprosthesis
HCPCS Level II code C1818 designates an integrated keratoprosthesis, an implanted prosthetic corneal device used in patients with advanced corneal pathology when standard penetrating or lamellar keratoplasty is not viable. This code captures a specialized ophthalmic surgical implant with implications for device coverage, surgical facility billing, and post-implant follow-up care. Nationally, accurate coding of keratoprosthesis procedures affects facility reimbursement, device-specific payment policies, and access to advanced corneal interventions.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on clinical context and service setting, plus what to expect from payer interactions: typical coverage considerations, relevant claims components, and where policy variation commonly occurs. The publication provides benchmarks for utilization and reimbursement patterns where available, summarizes pertinent payer policy trends, and highlights clinical factors that influence billing and coding for implanted keratoprosthesis procedures.
This executive summary is intended for administrators, coding professionals, and clinical leaders seeking a national perspective on HCPCS Level II code C1818, its role in ophthalmic surgical billing, and the key issues that affect payer coverage and facility claims handling.
Billing Code Overview
HCPCS Level II code C1818 describes an integrated keratoprosthesis, a surgically implanted prosthetic device designed to replace or augment the cornea for patients with severe corneal disease. The procedure represented by this code is an ocular surgical implant intended to restore or improve vision when conventional corneal transplantation is unsuitable.
Service type: Ophthalmic surgical implant
Typical site of service: Hospital inpatient or outpatient surgical center, ambulatory surgical center, or specialty ophthalmic surgical suite
Clinical & Coding Specifications
Clinical Context
An adult patient with severe corneal disease not amenable to conventional penetrating or lamellar keratoplasty undergoes placement of an integrated keratoprosthesis (C1818). Typical indications include end-stage corneal opacity from multiple failed grafts, severe ocular surface disease (for example, Stevens-Johnson syndrome or ocular cicatricial pemphigoid), chemical injury with loss of corneal clarity, or severe limbal stem cell deficiency with visual axis compromise. The clinical workflow begins with a comprehensive ophthalmic evaluation including best-corrected visual acuity, slit-lamp exam, corneal imaging, and assessment of eyelid and ocular surface health. Preoperative counseling and medical optimization (control of surface inflammation, treatment of ocular surface disease, systemic immunosuppression if indicated) are completed prior to scheduling.
On the day of service, the procedure is performed in an operating room or ambulatory surgery center under general or monitored anesthesia care. The integrated keratoprosthesis is implanted either as a primary reconstruction or as a revision after failed grafts. Postoperative care includes topical antimicrobials, anti-inflammatory agents, frequent follow-up visits to monitor device position, corneal-tissue interface, intraocular pressure, and management of complications (retroprosthetic membrane, device extrusion, endophthalmitis). Long-term surveillance and possible further procedures (membrane removal, glaucoma procedures) are part of care coordination.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|